Revenue: As of FY2026 Q3, the actual value is USD 11.21 K.EPS: As of FY2026 Q3, the actual value is USD 0.EBIT: As of FY2026 Q3, the actual value is USD -82.48 K.<h4>Segment Revenue</h4>Three Months Ended February 28: Total revenues were $11,205 in 2026, a decrease from $14,931 in 2025, primarily due to a reduction in clinical trial contracts . Clinical trials revenue was $11,200 in 2026, down from $14,931 in 2025 . Merchandise revenue increased to $5 in 2026 from $0 in 2025 . Consulting fees and Seminar fees remained $0 for both periods .Nine Months Ended February 28: Total revenues were $88,671 in 2026, a significant decrease from $268,066 in 2025 . Clinical trials revenue was $76,242 in 2026, compared to $267,098 in 2025 . Consulting fees generated $12,000 in 2026, up from $0 in 2025 . Seminar fees were $291 in 2026, compared to $0 in 2025 . Merchandise revenue was $138 in 2026, down from $968 in 2025 .<h4>Operational Metrics</h4>Three Months Ended February 28: Cost of revenues decreased to $3,045 in 2026 from $19,396 in 2025 . Gross profit was $8,160 in 2026, an improvement from - $4,465 in 2025 . Total operating expenses decreased to $101,419 in 2026 from $124,769 in 2025 . General and administrative expenses decreased by $23,344 to $26,828 in 2026 from $50,172 in 2025 . Contract labor decreased to $37,865 in 2026 from $45,382 in 2025 . Professional fees increased to $13,185 in 2026 from $9,730 in 2025 . Officer compensation increased to $11,089 in 2026 from $6,000 in 2025 . Operating loss decreased to - $93,259 in 2026 from - $129,234 in 2025 . Net loss for the quarter was - $103,933 in 2026, compared to - $181,243 in 2025 .Nine Months Ended February 28: Cost of revenues decreased to $21,688 in 2026 from $35,561 in 2025 . Gross profit was $66,983 in 2026, a decrease from $232,505 in 2025 . Total operating expenses were $330,903 in 2026, down from $518,970 in 2025 . Operating loss was - $263,920 in 2026, an improvement from - $286,465 in 2025 . Net loss for the nine months was - $303,546 in 2026, compared to - $337,076 in 2025 .<h4>Cash Flow</h4>Nine Months Ended February 28: Net cash used in operations was - $123,802 in 2026, an improvement from - $185,315 in 2025 . Net cash provided by financing activities was $110,940 in 2026, down from $185,108 in 2025 . Cash at the end of the period was $90 in 2026, significantly lower than $548 in 2025 .<h4>Key Financial Condition Indicators</h4><ul><li>As of February 28, 2026, Cannabis Bioscience International Holdings, Inc. had $90 in cash and cash equivalents and accounts receivable of $1,266 .</li><li>The company reported negative working capital of - $1,217,630 at February 28, 2026, compared to - $916,878 at May 31, 2025 .</li><li>The accumulated deficit was - $6,186,448 at February 28, 2026, compared to - $5,882,901 at May 31, 2025 .</li></ul><h4>Future Outlook and Strategy</h4>Cannabis Bioscience International Holdings, Inc.’s ability to continue as a going concern depends on the successful execution of its operating plan, which includes increasing sales of existing services and introducing new services . The company also needs to raise additional debt or equity financing to fund its business and repay its debts . There is no assurance that such capital can be obtained, and failure to do so could materially negatively impact operations or force termination .

Cannabis Bioscience International Holdings, Inc. | 10-Q: FY2026 Q3 Revenue: USD 11.21 K